Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?

Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?

15 Jun 2022

Use of sodium–glucose cotransporter-2 inhibitors (SGLT-2i) as first-line treatment for type 2 diabetes (T2D) delivers a comparable risk for myocardial infarction (MI), stroke, and mortality; a lower risk for hospitalization for heart failure (HHF)/mortality and HHF; and a similar safety profile, except for a higher risk for genital infections, when compared to treatment with metformin, a study has found.

Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?

15 Jun 2022
Beta-blocker use reduces daily physical activity

Beta-blocker use reduces daily physical activity

14 Jun 2022

Treatment with beta-blockers in hypertension may decrease daily physical activity but not maximal exercise performance, a study has found.

Beta-blocker use reduces daily physical activity

14 Jun 2022
Infection + vaccination = The best protection against COVID-19?

Infection + vaccination = The best protection against COVID-19?

13 Jun 2022